While the physiologic GIP action to potentiate insulin secretion and improve glycemia in healthy volunteers suggests pharmacologic agonism as a means to treat metabolic disease, this argument is not wholly commended by studies of patients with obesity and/or T2D. The gene discussed is GIP; the disease is obesity due to melanocortin 4 receptor deficiency.